# BUILDING SEX-SPECIFIC SYNTHETIC LETHALITY NETWORK IN CANCER - TEMP NAME

ALEXANDER TURCO

May 19, 2023

<sup>&</sup>lt;sup>1</sup> Department of, University, , ON, Canada

### **Notes**

### **Basic Basic Explanation of Synthetic Lethality**

Definition of synthetic lethality: Describes a situation in which mutations in two genes together result in cell death, but a mutation in either gene alone does not. Cancer cells that only have one mutated gene in a specific pair of genes can depend on the normal partner gene for survival. Interfering with the function of the normal partner gene may cause cancer cells to die. Studying synthetic lethality may help researchers learn more about the function of genes and develop new drugs to treat cancer (taken from https://www.cancer.gov/publications/dictionaries/cancer-terms/def/synthetic-lethality)

### What will my Project Explore

- There are sex differences in cancer (some more prevalent in males, some in females)
- From my understanding (May 9), what we are trying to do is build synthetic lethality networks in sex specific manner (basically can we build these synthetic lethal pairs in a sex-specific manner)
- Synthetic lethality is influenced by sex (maybe its a negative interaction, this can rescue cells)
- Been told to pay attention to the datasets utilized in the following papers so I know which data I can use for my project (gene expression data, CRISPR knockout datasets, siRNA, etc)

## Types of Data Utilized for Identifying Synthetic Lethal Relationships - How to discover therapeutically relevant SL interactions

- GTEx data: The Genotype-Tissue Expression project provides gene expression data across multiple human tissues can be utilized to identify tissue specific or context-specific synthetic lethal interactions by comparing gene expression profiles across different tissues or conditions
- used in (Cheng et al. 2021)
- CRISPR/Cas9 Screens allow researchers to systematically perturb genes and assess their effects on cellular phenotypes
   can provide genetic interaction data for identifying synthetic lethal relationships
- Current efforts to map SL interactions can be separated into 4 approaches Statistical approaches which leverage large
  populations of tumor genomes, evolutionary conservation, Direct experimentation in human cancer cell lines, combinatorial rather than single gene disruptions (Shen and Ideker 2018)

- TCGA is a comprehensive database that provides molecular characterization of various cancer types it provides whole genome sequencing data, transcriptomics data (RNA-seq), epigenomic data, clinical data, etc
- DepMap

### questions/confused

- when talking about SL, the literature often says inactivation of either gene (does this inactivation mean its completely removed or does it also entail mutations that could cause a lower expression of the gene?)
- I have not heard the literature mention the mechanisms of synthetic lethality so if both genes are affected, how does the cell actually die or have its viability reduced. Is it just due to the reduced expression of the genes involved?
- debMap
- X chromosome inactivation we usually have to infer for females which one is inactivated infer based on gene expression data etc
- cell line I use, know if it comes from male or female -
- Do I want to focus on differences in autosomal or sex chromosomes these are two different questions -
- Why do cancer cells have a tendency to lose or gain sex chromasomes
- Sex chromosome dosage??
- The biology behind a cell line

### **Potential Research Questions**

- 1. There are sex specific synthetic lethal gene pairs in certain types of cancers (are there gene combinations that result in synthetic lethality in males but not in females, or vice versa) -
- 2. Sex specific genetic modifiers affect synthetic lethality in cancer (Are there genes or genetic pathways that act as modifiers of synthetic lethality, specifically in males or females, potentially influencing treatment response or prognosis?)

#### PROPOSAL/WORKFLOW

MAY 18 - Today is my fourth day at UHN, this is the first workflow

- 1. Determine differentially expressed genes between Healthy (non-cancer) and Affected (cancer) Males and Females. Differential gene expression analysis can be utilized to find genes of interest in each of the sexes
  - We can obtain cancerous cell line data from CCLE (It has expression data, metadata for the samples, everything necessary for differential expression analysis)
  - Question: Are there any good databases for healthy cell lines
  - Question: In the study by Shohat and Shifman (2022), they inferred the presence of sex chromosomes in both male
    and female cancer cell lines (cancer cells have tendency to lose or gain sex chromosomes) Should I be taking the
    same approach for healthy cell lines and infer which chromosomes are present? (Nad mentioned overtime weird
    things can happen to these cell lines so it could be good to check)
  - Possibility that there will be much more data on cancer cell lines than healthy cell lines which could affect results
     an alternative approach is to directly compare healthy and affected cell lines (for example Healthy breast Tissue and Breast Cancer Tissue) individually as opposed to having many more cancerous cell lines than healthy cell lines and grouping them together.
- 2. Identify potential synthetic lethal partners of the genes that were found to be differentially expressed in each sex
  - This can be done through utilizing CRISPR-Cas9 knockout data there is CRISPR knockout data pertaining to cancerous cell lines on CCLE database have to look in to how to find the interactions (I have seen methods like ISLE but I don't know how relevant it would be here)
  - Since the genes of interest were differentially expressed in cancer cell lines, does this mean they are potentially
    contributing to cancer and hence finding specific synthetic lethal partners to these genes could lead to finding sexspecific potential drug targets?
- 3. Assess the differences in synthetic lethal partners in male vs females we may want to exclude genes that we know for sure are only in one sex such as testicular genes excluding these means we will focus on the differences but it could also be good to keep genes known to be found in one sex as validation/confirmation that they are very highly differentially expressed in each sex (to confirm DGE analysis).

### **References**

- Cheng K, Nair N U, Lee J S, and Ruppin E (2021). Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity. Science advances 7(1), eabc2100.
- Lee J S, Nair N U, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg A V, et al. (2021). Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell 184(9), 2487–2502.
- Shen J P and Ideker T (2018). Synthetic lethal networks for precision oncology: promises and pitfalls. Journal of molecular biology 430(18), 2900–2912.
- Shohat S and Shifman S (2022). Gene essentiality in cancer cell lines is modified by the sex chromosomes. Genome Research 32(11-12), 1993–2002.